North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Similar documents
ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile

DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Glenmark Pharmaceuticals Inc., USA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bionure Farma SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Median Kliniken GmbH & Co. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile

Mindray Medical International Limited (MR) - Medical Equipment - Deals and Alliances Profile

Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Paramount Mining Corporation Limited (PCP) - Metals and Mining - Deals and Alliances Profile

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

The Walt Disney Company - Strategy, SWOT and Corporate Finance Report

McCain Foods Limited, Inc. - Strategic SWOT Analysis Review

Gap, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Vorwerk and Co. KG - Strategy, SWOT and Corporate Finance Report

Kohler Co. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Phone: +44 (0) or BioPortfolio Limited

Maruti Suzuki India Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Surgical Sutures Market By Product Type [Automated Suturing Devices (Disposable Automated Suturing Devices, And Re-Usable Automated Suturing

Compression Therapy - Medical Devices Pipeline Assessment, 2017

Critical Limb Ischemia - Pipeline Review, H1 2017

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

Johnson & Johnson (JNJ) - Medical Equipment - Deals and Alliances Profile

Digital Health Funding and M&A

Generics Series: Authorized Generics Analysis Stemming the Generics Tide

United States Sterilization Equipment Market Outlook to 2021

Venture Capital Report

Venture Capital Report

peace of mind For from development to commercial supply

VentureSource China -- 1Q 2014

Global Paper Stationery Market Research Report 2016

Roche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo Dr. Axel Braun F. Hoffmann La Roche Ltd.

EXAMINATION NUMBER ONLY.

Venture Capital Report

Cherry AB. Investing in a broad gaming portfolio. CEO Anders Holmgren GP Bullhound 6 December 2017

Master Class : Excellence in Private Equity & Deal Structuring

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

I Overview. II Hallmarks of Turnpoint Group. III Corporate Financial Services. IV Assignments. V Clients. VI Market Segments

Chartwell Introduction and AEC Capabilities

VentureSource China -- 3Q 2014

PitchBook. Bet ter Data. Bet ter Decisions. 4Q 2012 Private Equity. Company Inventory. Report. Sponsored by:

Venture Capital Report

Global and China Industrial Robot Industry Report, Sep. 2013

GLOBAL RISK AND INVESTIGATIONS JAPAN CAPABILITY STATEMENT

Global Absolute Pressure Transmitters Market Research Report 2016

Venture Capital Report

Global DAW Software Market Research Report 2016

A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei

Intellectual property governance and strategic value creation:

State of Licensing 2011 Update

April By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW

World Offshore Wind Market Forecast Prospects, Technologies, World Markets

Dealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved.

Global and China Industrial Robot Speed Reducer Industry Report, Jun. 2014

Transaction Services. Member of Invest Europe and SECA Swiss Priva te E quity & Corporate Finance Association

Indoor Positioning and Navigation System Market Research Report- Forecast 2023

GLOBAL PRIVATE EQUITY Report Charts

JOHN JACK R. TUPMAN, JR CURRICULUM VITAE

Military Robotics - Emerging Trends and Future Outlook. Reference code: DF4580PR Published: July 2015 Single user price: US$1950

Pharma - Biotech Collaborations: Optimizing Success, Minimizing Risk and Maintaining Alignment

Headcount: Hidden Founded in Hidden. Assets Under Management: Hidden Hidden Hidden Hidden NewStar Business Credit Closes $15MM Credit for Atlas Group

New York Bar admission (or eligibility to obtain admission promptly) is required.

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd.

Equity investment includes private equity (PE) investment and venture capital (VC) investment. In 2009, there were 542 equity

4 th Quarter Earnings Conference Call

CANADIAN PRIVATE EQUITY BUYOUT REVIEW

KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018

UNITED INTERNET. Business Applications Strategic Partnership with Warburg Pincus. November 8, Investor Presentation November 8, 2016

2 nd Quarter Earnings Conference Call

Omeros Raises More Than $63 Million in Financing

January Bob DeSutter Managing Director Co-Head of Health Care

M&A Update 1H Proven. Focused. Trusted. Accounts Receivable Management Healthcare IT Revenue Cycle Management

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018

4 th Quarter Earnings Conference Call

JAPAN M+A A N N u A l r e v i e w

Find and analyse the most relevant patents for your research

Advisors. Firm Overview

ALANCO TECHNOLOGIES INC

Global Sequins Apparels Market Research Report 2016

Mara H. Rogers, Partner Norton Rose Fulbright

gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) Web gellerbp.

CHARTER PACIFIC SIGNS SHARE PURCHASE AGREEMENT TO ACQUIRE 100% OF THE MICROLATCH GROUP

Britco Group. Transaction snapshot

China Ophthalmic Hospital Industry Report, May 2013

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA

Ying Li. Proskauer.com. Partner. Hong Kong Beijing New York

Cannabis Practice Group

Transcription:

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0)1300 321501 or Email: reportstore@bioportfolio.com 2

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Summary North China Pharmaceutical Group Corp. (NCPC) is a pharmaceutical company that manufactures and distributes antibiotic bulks and formulations, vitamins and nutrition products, biotech products, immunosuppressant and pesticide to veterinary drugs. The company s products include antibiotics, penicillin, amoxicillin, streptomycin sulfate, cefradine, 7-ADCA, vitamin C and vitamin B12. It offers its products in dosage forms such as capsules, granules, injections, freeze-dried powder for injection, immunologic and biologic agent, nutrition supplement, tablets, veterinary and biocides products, powder for injection, antineoplastic agents, oral suspension and other formulations. The company has operations across China. NCPC is headquartered in Shijiazhuang, China. North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma etrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. 3

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Additional Details Publisher : Global Data Reference : GDPH221350D Number of Pages : 22 Report Format : PDF Publisher Information : 4

5

Table Of Contents for North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Table of Contents Table of Contents 2List of Tables 3List of Figures 4North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 8North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deal Details 9Equity Offering 9North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9North China Pharma Completes Private Placement Of Shares For US$471 Million 11North China Pharma Announces Private Placement Of Common Stock For US$466 Million 12Debt Offering 14North China Pharma Announces Public Offering Of Notes For US$73 Million 14Acquisition 15NCPC To Sell North China Pharma Huasheng For US$12 Million 15NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 16NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 17North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 18Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 19North China Pharmaceutical Group Corp. - Key Competitors 20Locations And Subsidiaries 21Head Office 21Other Locations & Subsidiaries 21Appendix 22Methodology 22About GlobalData 22Contact Us 22Disclaimer 22 6

List Of Tables in North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile List of Tables North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Key Facts 1 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 1 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 8 North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9 North China Pharma Completes Private Placement Of Shares For US$471 Million 11 North China Pharma Announces Private Placement Of Common Stock For US$466 Million 12 North China Pharma Announces Public Offering Of Notes For US$73 Million 14 NCPC To Sell North China Pharma Huasheng For US$12 Million 15 NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 16 NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 17 North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 18 Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 19 North China Pharmaceutical Group Corp., Key Competitors 20 North China Pharmaceutical Group Corp., Other Locations 21 North China Pharmaceutical Group Corp., Subsidiaries 21 7

List Of Figures, Charts and Diagrams in North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile List of Figures North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6 North China Pharmaceutical Group Corp., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7 8

How to Buy... North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Email: Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $250 Single User Price $500 Site License Price $750 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will email you the invoice with a payment link) Direct Wire Transfer (we will email you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0)1300 321501 We will be delighted to give you our personal attention. 9